NORTHWEST BIOTHERAPEUTICS, INC. Purchase AgreementPurchase Agreement • August 19th, 2014 • Northwest Biotherapeutics Inc • Pharmaceutical preparations • New York
Contract Type FiledAugust 19th, 2014 Company Industry JurisdictionNorthwest Biotherapeutics, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several Initial Purchasers listed in Schedule 1 hereto (the “Initial Purchasers”), for whom you are acting as Representative (the “Representative”), an aggregate of $17,500,000 principal amount of its 5.00% Convertible Senior Notes due 2017 (the “Securities”). The Securities will be convertible into cash, shares (the “Underlying Securities”) of common stock of the Company, par value $0.001 per share (the “Common Stock”), or a combination thereof, at the Company’s election, subject to certain limitations as set forth in the Indenture (as defined herein). The Securities will be issued pursuant to an Indenture to be dated as of the Closing Date (as defined below) (the “Indenture”), between the Company and The Bank of New York Mellon as trustee (the “Trustee”).